The advent of immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, has revolutionized the treatment landscape for cancer, making the combination of chemotherapy and immunotherapy a promising treatment strategy for NSCLC (2). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.